Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: stephen samborski who wrote (3411)	2/15/2000 2:42:00 PM
From: Bruce Cullen	Read Replies (2) \| Respond to of 3702

I agree, this news is great. TCLN is proving that more revenue sources are on the way, listen to the conference calls, this should ensure that the needed money for TCLN is on the way and they should continue their push into new cancer therapy frontiers. Strong Buy! Bruce Cullen sherwoodcoastsgroup.com See SCG recommendations, disclaimers & stories at top of link.

To: stephen samborski who wrote (3411)	2/15/2000 2:47:00 PM
From: AurumRabosa	Respond to of 3702

Techniclone Completes Exclusive Worldwide License Transaction for Permeability Enhancing Protein and Announces Issuance of Patent Tustin, CA. (Business Wire) Feb 15, 2000 - Techniclone Corporation (TCLN) today announced it has completed an exclusive worldwide licensing transaction with the University of Southern California for its Permeability Enhancing Protein (PEP). The Company also disclosed that US Patent No. 6008319 was issued for this protein and will become part of Techniclone's intellectual property under the terms of the licensing agreement. The terms of the licensing agreement were not disclosed. The PEP technology is a vital piece of Techniclone's Vasopermeability Enhancing Technology which is designed to increase the uptake of chemotherapeutic agents into tumors. It is designed to be used in conjunction with Techniclone's Vasopermeation Enhancement Agent (VEA) technology platform. Techniclone recently announced the issuance of a key patent in the VEA area. Alan Epstein, M.D., Ph.D, Professor of Pathology at the University of Southern California and the inventor of both the VEA technology and the discoverer along with colleague Dr. Leslie Kwhali, of the PEP molecule, stated, "The PEP technology in conjunction with the overall VEA platform technology completes an already strong package with high potential for application in the field of cancer therapeutics and diagnostics. I am excited about working with the new Techniclone management to bring this technology to commercialization." The PEP molecule is a segment of a cytokine (cell messenger) called IL-2. The PEP molecule appears to allow the tumor to become more permeable to the uptake of drugs while not having toxic side-effects. The PEP patent covers the use of the molecule in conjunction with targeting molecules such as antibodies to specifically enhance the uptake of drugs in most solid tumors. Preclinical studies in animal models have shown that drug uptake can be increased up to 400% in specific instances by using the VEA technology (including the PEP molecule) as a pretreatment. Dr. John Bonfiglio, Techniclone's Interim President, stated, "The completion of the licensing deal and the issuance of the PEP patent are the last key pieces to the VEA technology platform. Techniclone has now complete access to this powerful and broad platform technology. This technology fits very well into the drug development efforts of many pharmaceutical companies. We look forward to working with Dr. Epstein and his research group to develop this technology further while we simultaneously advance discussions on licensing this technology to companies in the cancer therapeutics area who are interested in delivering more drug to the tumor with potentially fewer side effects." The New England Research Application Center (Source: Geriann P. Park and Anna Crull, "Cancer Treatment and Diagnostic Products," report YC-047N) estimates that $7.6 billion will be spent annually on chemotherapeutic treatments in the year 2000, reflecting a 9% annual growth rate - a market Techniclone will target with its proprietary and patent-protected technology. All preclinical studies for the VEA technology were conducted at the University of Southern California (USC), under the leadership of Dr. Alan Epstein, M.D., Ph.D., the inventor of the VEA technology. Results of the Dr. Epstein's preclinical studies in the VEA technology have been corroborated by two physicians at Keio University in Tokyo, Japan. These researchers achieved similar increases in tumor uptake of anti-cancer agents through pretreatment with the Vasopermeation Enhancement concept. Findings of this study, which was conducted independently from Techniclone, were presented in 1997 at the Annual Society of Nuclear Medicine Meeting. Company Overview: Techniclone Corporation is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer, primarily based on its ''collateral targeting technologies.'' These technologies therapeutically target cell structures and cell types, rather than surface cancer cells, as a means to attack solid tumors, without causing damage to surrounding healthy tissue. The Company has three collateral technologies: Cotara(TM), Vasopermeation Enhancement Agents (VEA) , and Vascular Targeting Agents (VTA). The Company also has a direct tumor targeting agent called Oncolym (R) for the treatment of advanced non-Hodgkin's B-cell Lymphoma which has been licensed to Schering AG, Germany, which is now responsible for all existing and future Oncolym® clinical trial programs as well as marketing. Additional information on the Company and its products can be found at techniclone.com Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the Company's expectations as a result of risk factors discussed in Techniclone's reports on file with the US SEC, including, but not limited to, the Company's report on Form 10K for the year ended April 30, 1999 and Form 10Q for the quarter ended October 31, 1999. Contact: DeMonte Associates Cynthia DeMonte 212-420-0088